Abstract Body (Do not enter title and authors here): Background: Semaglutide is increasingly used in the management of type 2 diabetes mellitus and
obesity. Ensuring safety of this medication is crucial for its clinical use. This meta-analysis
evaluates the safety profile of semaglutide across patient populations and treatment durations.
Methods: Randomized controlled trials assessing the safety of semaglutide versus placebo, with
specified treatment durations were identified. The primary outcome was occurrence of any
cardiovascular adverse events. Secondary outcomes included sudden cardiac death, adverse events
leading to death, adverse events, gastrointestinal side effects, occurrence of hypoglycemia and
new-onset neoplasm.
Results: A total of 23 studies met the inclusion criteria with a combined sample size of 57,911
participants. The meta-analysis revealed that the adverse event associated with semaglutide is
gastrointestinal in nature (nausea and vomiting). No significant differences were observed between
semaglutide and comparator groups. (See Figure 1)
Conclusion: Semaglutide appears to have a favorable safety profile across diverse patient
populations and treatment durations, supporting its continued use in the management of type 2
diabetes mellitus and obesity. It is generally well-tolerated, with a low incidence of adverse events.
Clinicians should be aware of these findings and monitor patients accordingly. Further long-term
studies are warranted to assess the safety of semaglutide in clinical practice.